EP 65

Orbiting around Big Pharma

The pharmaceutical industry is undergoing a profound structural shift, with big pharma companies deploying massive supercomputing platforms to accelerate drug discovery. This shift raises concerns about the potential for corporate monopolies and the suppression of unconventional chemistry. In this episode, we explore the implications of this new playbook and the role of academia in maintaining a pluralistic discovery ecosystem.

big pharmaplatform strategydrug discoveryartificial intelligencemachine learningbiotechacademia

play_arrowListen to episode

Key Concepts

Platform Strategy

Big pharma companies are adopting a platform strategy to accelerate drug discovery.
This strategy involves building a foundational platform layer using decades of proprietary R&D memory.
The platform consists of four distinct layers: data, compute, model, and ecosystem.

Data Layer

The data layer is the most valuable asset, as it contains the historical memory of the company, including failures.
The data layer is used to train predictive models, which are then used to accelerate drug discovery.

Compute Layer

The compute layer provides raw power, with massive supercomputing clusters capable of thousands of petaflops.
The compute layer is used to process large amounts of data and perform complex calculations.

Model Layer

The model layer is the engine that converts historical data and raw compute into reusable predictive models for drug discovery.
The model layer is used to predict the efficacy and safety of potential drugs.

Ecosystem Layer

The ecosystem layer is where the strategy activates, with the pharma company exposing its model layer to the outside world.
The ecosystem layer pulls external startups and academic labs into the pharma company's network.

Academia's Role

Academia has a crucial role to play in maintaining a pluralistic discovery ecosystem.
Academia generates biological ground truth and provides an independent counterweight to corporate platforms.

Episode Summary

check_circleBig pharma companies are adopting a platform strategy to accelerate drug discovery, similar to the tech industry's platform playbook.
check_circleThis strategy involves building a foundational platform layer using decades of proprietary R&D memory and inviting the biotech industry to build on top of it.
check_circleThe platform consists of four distinct layers: data, compute, model, and ecosystem.
check_circleThe data layer is the most valuable asset, as it contains the historical memory of the company, including failures, which are used to train predictive models.
check_circleThe compute layer provides raw power, with massive supercomputing clusters capable of thousands of petaflops.
check_circleThe model layer is the engine that converts historical data and raw compute into reusable predictive models for drug discovery.
check_circleThe ecosystem layer is where the strategy activates, with the pharma company exposing its model layer to the outside world and pulling external startups and academic labs into its network.
check_circleThis platform strategy raises concerns about the potential for corporate monopolies and the suppression of unconventional chemistry.
check_circleAcademia has a crucial role to play in maintaining a pluralistic discovery ecosystem, by generating biological ground truth and providing an independent counterweight to corporate platforms.
check_circleThe dual track strategy for academic translational programs involves building open source public models and engaging with corporate platforms under strict governance frameworks.

Full Transcript

Discussion

Join the discussion — sign in to leave a comment.